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Abstract: Human chymase is a very important target for the treatment of cardiovascular 
diseases. Using a series of theoretical methods like pharmacophore modeling, database 
screening, molecular docking and Density Functional Theory (DFT) calculations, an 
investigation for identification of novel chymase inhibitors, and to specify the key factors 
crucial for the binding and interaction between chymase and inhibitors is performed. A 
highly correlating (r = 0.942) pharmacophore model (Hypo1) with two hydrogen bond 
acceptors, and three hydrophobic aromatic features is generated. After successfully 
validating “Hypo1”, it is further applied in database screening. Hit compounds are 
subjected to various drug-like filtrations and molecular docking studies. Finally, three 
structurally diverse compounds with high GOLD fitness scores and interactions with key 
active site amino acids are identified as potent chymase hits. Moreover, DFT study is 
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performed which confirms very clear trends between electronic properties and inhibitory 
activity (IC50) data thus successfully validating “Hypo1” by DFT method. Therefore, this 
research exertion can be helpful in the development of new potent hits for chymase. In 
addition, the combinational use of docking, orbital energies and molecular electrostatic 
potential analysis is also demonstrated as a good endeavor to gain an insight into the 
interaction between chymase and inhibitors. 
Keywords: chymase; pharmacophore; molecular docking; in silico screening; density 
functional theory; molecular electrostatic potential. 
 
1. Introduction 
Raised blood pressure, especially systolic pressure (hypertension), is one of the striking factors 
inducing various diseases like heart failure, stroke, myocardial infarction and arterial aneurysm, and is 
a leading cause of chronic kidney failure [1]. A treatment of hypertension is to decrease the circulating 
volume and/or to slack the blood vessels [2]. Angiotensin II has important roles not only in the 
regulation of blood pressure but also in the development of vascular wall remodeling [3]. Conversion 
of angiotensin I (Ang I) to angiotensin II (Ang II) is catalyzed by well-known angiotensin-converting 
enzyme (ACE), which is a metallo-proteinase with dipeptidyl-carboxypeptidase activity. However, 
chymase (EC 3.4.21.39) which is a chymotrypsin-like enzyme expressed in the secretory granule of 
mast cells, also catalyzes the production of angiotensin II in vascular tissues even when ACE is 
blocked (Figure 1).  
Figure 1. Chymase-dependent conversion of angiotensin I to angiotensin II and precursors 
of TGF-β and MMP-9 to their active forms. 
 
Chymase converts Ang I to Ang II with greater efficiency and selectivity than ACE [4]. The rate of 
this conversion by chymase is approximately four fold higher than ACE. Chymase shows enzymatic 
activity immediately after its release into the interstitial tissues at pH 7.4 following various stimuli in 
tissues. Since chymase has no enzymatic activity in normal tissues, chymase inhibitors are expected to 
have high safety because chymase inhibitors may not have an effect on any other targets in normal  
tissues [5]. In order to generate Ang II, human, monkey, dog and hamster chymases cleave the 
angiotensin I at Phe8-His9 peptide bond. Chymase also converts precursors of transforming growth 
factor-β (TGF-β) and matrix metalloproteinase (MMP)-9 to their active forms thus contributing to Int. J. Mol. Sci. 2011, 12 9238 
 
vascular response to injury. Both TGF-β and MMP-9 are involved in tissue inflammation and fibrosis, 
resulting in organ damage [6]. Previous studies have demonstrated the involvement of chymase in the 
escalation of dermatitis and chronic inflammation pursuing cardiac and pulmonary fibrosis [7]. 
Therefore, inhibition of chymase is likely to divulge therapeutic ways for the treatment of 
cardiovascular diseases, allergic inflammation, and fibrotic disorders. Chymase inhibition may also be 
useful for preventing the progression of type 2 diabetes, along with the prevention of diabetic 
retinopathy [8]. Moreover, the role of chymase in inflammation has prompted its restorative value in 
diseases such as chronic obstructive pulmonary disease (COPD) and asthma [9]. 
Chymase inhibitors are imperative for elucidation of the physiological functions of chymase and 
potentially useful therapeutic agents. Several chymase inhibitors such as sulfonyl fluoride derivatives [10], 
Boc-Val-Pro-Phe-CO2Me [11], Z-Ile-Glu-Pro-Phe-CO2Me, (F)-Phe-COGlu-Asp-ArgOMe [12],   
N-(2-Naphthyl) carboxamido derivatives [13], N-(2,2-dimethyl-3-(N-(4-cyanobenzoyl)amino) 
nonanoyl)-L-phenylalanine ethyl ester [14], 3-benzylazetidine-2-one derivatives [15],   
1,3-diazetidine-2,4-dione derivatives [16], methyllinderone derivatives [17], chloromethyl ketone 
derivatives [18], 1-oxacephem derivatives [19], and 3-(phenylsulfonyl)-1-phenylimidazolidine-2,4-dione 
derivatives [20] have been reported previously. In general, chymase inhibitors readily decompose in 
plasma, thus the stability of the chymase inhibitors in human plasma has always been a matter of great 
concern. For a drug candidate, it is essential to enhance the stability of the active compound in human 
plasma. So, there is always a dire need to search for more stable inhibitors with high activity against 
human chymase. 
Many studies have indicated that computational approaches, such as predicting drug-target interaction 
networks [21], prediction of body fluids [22], predicting HIV cleavage sites in proteins [23,24], predicting 
protein metabolic stability [25], predicting signal peptides [26], identification of DNA Binding 
Proteins [27], predicting the network of substrate-enzyme-product triads [28], predicting protein 
subcellular locations [29,30], predicting proteases and their types [31], predicting antimicrobial 
peptides [32], predicting membrane proteins and their types [33], predicting GPCRs and their   
types [34], identifying nuclear receptor subfamilies [35], predicting gram-negative bacterial protein 
cellular locations [36], and predicting transcriptional activity of multiple site p53 mutants [37], can 
provide many useful insights and data for which it would be time-consuming and costly to obtain by 
experiments alone. Actually, these data, combined with the information derived from the structural 
bioinformatics tools (see, e.g., [38]), can timely provide very useful insights for both basic research 
and drug development. In view of this, the present study attempts to develop a new computational 
modeling method in the hopes it may become a useful tool for the drug development. 
A quantitative structure-activity relationship (QSAR) study is a helpful approach to quantitatively 
understand the relationships between molecular structures of inhibitors and their biological   
activities [39–46]. Pharmacophore modeling and 3D-QSAR studies have been successfully applied 
previously for various drug discovery research, including glycoprotein (GP) IIb/IIIa antagonists,   
H3-antihistaminics, and dihydrofolate reductase inhibitors [47–51]. Electronic molecular features such 
as electron density, frontier molecular orbital density fields such as lowest unoccupied molecular 
orbital (LUMO), highest occupied molecular orbital (HOMO) and molecular electrostatic map have 
also been revealed to be significant in other QSAR studies to explain biological activity and molecular 
properties [52]. The HOMO density field was useful in a study of ACE inhibitors, and the LUMO Int. J. Mol. Sci. 2011, 12 9239 
 
density field was found to be important for explaining the TA100 mutagenicity [53,54]. Thus, 
determining molecular electronic properties responsible for the potent activity of selected chymase 
inhibitors should illuminate the fundamental molecular level forces responsible for their potency. 
Various QSAR studies for chymase inhibitors have also been performed. The QSAR analysis of 
anhydride-type chymase inhibitors showed that aromatic substituents played an important role in 
determining the inhibitory potency of the compounds [55]. While, Hayashi and coworkers showed that 
introduction of various substituents in chloromethyl ketone derivatives resulted in a variation in their 
activity against human chymase [18]. A 3D QSAR model for the identification of stable chymase 
inhibitors has also been developed by Yuuki et al. 2003 [56].
 
The subject of the present study is to develop QSAR models and explore the key molecular features 
of chymase inhibitors influencing the protein-ligand binding and interaction, by exploring the 
dependence of inhibitory activities upon various physiochemical properties of these compounds. In 
order to accomplish these tasks, an exclusive computational strategy is applied by using various QSAR 
model building techniques such as pharmacophore modeling, molecular docking, and Density 
Functional Theory (DFT) (Figure 2). 
Figure 2. Flow chart elucidating the computational strategy applied in this study. 
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In the first phase of calculations, a pharmacophore model (Hypo1) comprising key chemical 
features for the identification of novel and diverse chymase inhibitors has been generated. After 
validation, this pharmacophore model is used as a 3D structural search query to find new classes of 
compounds with similar chemical features from chemical databases. The obtained hits are scrutinized 
based on their estimated activity and calculated drug-like properties. Molecular docking is also 
performed for the evaluation of compounds for important binding site interactions and affinity. Finally, 
we have carried out DFT-based QSAR studies on a set of chymase inhibitors retaining structural 
diversity and a wide biological activity range, along with potent hits retrieved by newly developed 
pharmacophore model (Hypo1). The objective of this DFT study is two-fold. One purpose is to derive 
the QSAR model itself and the other is to scrutinize the usefulness of conceptual DFT quantities. 
Moreover, it also served as a validation technique for the generated pharmacophore model. Various 
electronic properties such as LUMO, HOMO, and locations of molecular electrostatic potentials, are 
computed. The results of this study are expected to explore the crucial molecular features contributing 
to binding specificity and be useful for understanding the molecular mechanism by which   
these compounds act and can be further utilized to get compounds with better activity by   
rational modification. 
2. Results and Discussion 
2.1. Pharmacophore Modeling 
One of the main objectives of the present study is to generate a pharmacophore model for the 
identification of novel chymase inhibitors. To accomplish this, ten hypotheses with imperative statistical 
parameters were generated by HypoGen module of DS using a training set of 20 compounds (Figure 3). 
The hypotheses are generated with cost functions and correlation values by which they are 
estimated. The fixed cost, total cost and null cost values are calculated by HypoGen module during the 
hypotheses generation. The fixed cost is the lowest possible cost representing a hypothetically simplest 
model that fits all data perfectly, whereas the null cost value is equal to the maximum occurring error 
cost. For a more statistically significant hypothesis, there should be greater difference between these 
two cost values. The possibility of correlating the experimental and estimated activity data enhances to 
75–90% with a cost difference of 40–60 bits between the total and null cost values [57,58]. In the 
present work, the null cost value of the top 10 hypotheses is 182.366 and the fixed cost value is 75.791. 
Thus, a difference of 106.575 bits between fixed cost and null cost consigns to a meaningful 
pharmacophore model. Moreover, the total cost of the generated hypothesis should be closer to the 
fixed cost. All ten generated hypotheses scored a total cost closer to the fixed cost which leads to a 
good model. Statistically significant factors which include cost values, correlation coefficients (r), 
pharmacophore features, and root mean square deviations (RMSDs) of all 10 hypotheses are listed  
in Table 1. Int. J. Mol. Sci. 2011, 12 9241 
 
Figure 3. 2D molecular structures of training set compounds. 
 
Table 1. Statistical details for top 10 scoring hypotheses. 
Hypothesis Total  cost ΔCost 
a   RMSD (Å) Correlation (r) Features 
1  89.663  92.703  1.176  0.942  HBA, HBA, HY-AR, HY-AR, HY-AR
2  91.454  90.912  1.25  0.934  HBA, HBA, HY-AR, HY-AR, HY-AR
3  94.811  87.555  1.348  0.924  HBA, HY-AR, HY-AR, RA 
4  95.086  87.28  1.388  0.919  HBA, HBA, HY-AR, HY-AR, HY-AR
5  95.379  86.987  1.387  0.919  HBA, HY-AR, RA, RA 
6  95.458  86.908  1.396  0.918  HBA, HBA, HY-AR, HY-AR, HY-AR
7  95.656  86.71  1.406  0.916  HBA, HBA, HY-AR, HY-AR, HY-AR
8  95.855  86.511  1.409  0.916  HBA, HBA, HY-AR, HY-AR, HY-AR
9  95.538  86.828  1.411  0.916  HBD, HY-AR, RA, RA 
10  96.124  86.242  1.421  0.915  HBA, HBA, HY-AR, HY-AR, HY-AR
Null cost = 182.366, fixed cost = 75.791, configuration cost = 16.606; all cost values are in bits;  
a ΔCost = Null cost − Total cost; Abbreviations used for features: HBA, Hydrogen-bond acceptor; 
HY-AR, hydrophobic aromatic; RA, ring aromatic; HBD, Hydrogen-bond donor. 
The configuration cost enumerates the entropy of the hypothetical space and its value should not 
exceed a maximum value of 17 for a significant pharmacophore model [59,60]. The configuration cost 
value of 16.601 was obtained for this pharmacophore generation calculation. 
Seven of the 10 hypotheses were made of five pharmacophoric features while another three had 
shown four features. The HY-AR was the common feature among all hypotheses. Nine of the Int. J. Mol. Sci. 2011, 12 9242 
 
10 hypotheses had Hydrogen-bond acceptor (HBA), three hypotheses had ring aromatic (RA) while 
only one hypothesis was made of hydrogen bond donor (HBD). Hypo1 consists of two HBA and three  
HY-AR features and scored the better correlation and cost difference values. The RMSD value 
indicates the quality of “prediction” for the training set. The RMSD of all ten hypotheses ranged from 
1.176 to 1.421 Å while the Hypo1 showed the lowest RMSD value of 1.176 Å. The correlation 
coefficient for the Hypo1, 0.942, represents a good correlation by linear regression of the geometric fit 
index. All these results construe that Hypo1 is the best ranking pharmacophore model among other 
hypotheses (Figure 4). 
Figure 4. The pharmacophore model, Hypo1, showing two hydrogen-bond acceptors 
(HBAs) and three hydrophobic aromatic (HY-AR) features (a) and with distance 
constraints (b). 
 
On the basis of the activity, compounds belonging to training and test sets were categorized into 
activity scales: most active (++++, IC50 (inhibitory concentration) < 20 nM); moderately active (+++, 
≥20 IC50 < 200 nM); less active (++, ≥200 IC50 < 2000 nM); inactive (+, IC50 ≥ 2000 nM). Activities 
of all compounds were estimated based on the best ranking pharmacophore model, Hypo1. The 
experimental and estimated activity values for the 20 training set compounds based on Hypo1 are 
listed in Table 2.  
Table 2. Experimental biological activity data and estimated IC50 values of training set 
compounds based on pharmacophore model Hypo1. 
Compound 
Experimental 
activity (nM) 
Estimated 
activity 
Error 
Activity 
scale 
a 
Estimated 
activity scale 
1 0.46  0.27  −1.7 ++++ ++++ 
2 2.1  1.9  −1.1 ++++ ++++ 
3 11  16  1.4  ++++  ++++ 
4 20  49  2.5  +++  +++ 
5 57  50  −1.1 +++  +++ 
6 91  80  −1.1 +++  +++ 
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Table 2. Cont. 
7 110  650  5.9  +++  ++ 
8 170  170  1  +++  +++ 
9 220  720  3.3  ++  ++ 
10 250  650  2.6  ++  ++ 
11 360  710  2  ++  ++ 
12 410  760  1.9  ++  ++ 
13 730  660  −1.1 ++  ++ 
14 900  610  −1.5 ++  ++ 
15 1300  930  −1.4 ++  ++ 
16 1600  650  −2.6 ++  ++ 
17 2200  860  −2.6 +  ++ 
18 3000  850  −3.5 +  ++ 
19 3500  830  −4.2 +  ++ 
20 5900  4800  −1.2 +  + 
a Activity scale: most active (++++, IC50 < 20 nM); moderately active (+++, ≥20 IC50 < 200 nM); 
less active (++, ≥200 IC50 < 2000 nM); inactive (+, IC50 > 2000 nM). 
Analysis of the activity prediction of training set compounds revealed that all the most active 
compounds were predicted in the same scale, whereas only one moderately active compound was 
estimated as less active and three inactive compounds were estimated as less active compounds among 
the 20 compounds of training set. The estimated activity values of most and least active compounds of 
the training set based on Hypo1 were 0.27 and 4800 nM, respectively, which are very close to that of 
their experimental activity values (0.46 and 5900 nM). This result revealed that the structural 
characteristics which can explain the difference in their biological activities are present in   
Hypo1 (Figure 5a). 
Figure 5. Mapping of most active compound 1 (a) and least active compound 20 (b) of 
training set over pharmacophore model Hypo1. 
 
The most active compound 1 could map all the features of the best pharmacophore model, Hypo1, 
with a fit value of 9.04. The carbonyl oxygen atoms attached with the piperazine ring and azetidinone 
moiety were mapped onto the two HBA features. All three phenyl rings present in this most active 
compound mapped over three HY-AR features. The least active compound 20 in the training set maps 
Hypo1 with a fit value of 4.79 missed two HY-AR features as compared to compound 1. Carbonyl Int. J. Mol. Sci. 2011, 12 9244 
 
group of imidazolidine-dione and the only carboxyl group of this least active compound mapped both 
the HBA features whereas the phenyl ring attached to the imidazolidine-dione mapped over one of the 
HY-AR features (Figure 5b).  
2.2. Pharmacophore Validation  
2.2.1. Test Set Prediction Method 
The validation of suggested pharmacohore model, Hypo1, was performed by two different 
validation methods, namely, test set prediction and Fischer randomization methods. A test set 
containing 97 compounds, representing diverse activity classes and different functional groups, is used 
in this validation process. These test compounds were imported into the DS and diverse conformers 
were built in the same manner as for training set compounds. The estimated activities of these test set 
compounds were calculated based on the geometric fit of these compounds over Hypo1. Analyses of 
the estimated activities of test set compounds demonstrated remarkable results. From the 97 test set 
compounds, 94 compounds showed error values less than 5 which is hardly different from the 
experimental and estimated activity values (Table 3). 
Table 3. Test set compounds listed with their experimental, estimated activities and error values. 
Name 
IC50 nM 
Error 
c 
Activity scale 
d
Name
IC50 nM 
Error 
Activity scale 
Exp. 
a Est. 
b Exp. Est. Exp.  Est. Exp.  Est. 
21 0.5 0.48  −1.0 ++++ ++++  70  500  491.7  −1.0 ++  ++ 
22 1 1.00  −1.0 ++++ ++++  71  550  592.4  1.0  ++  ++ 
23 2  65.84  32.9  ++++ +++  72  580  579.668  −1.0 ++  ++ 
24 3.1 3.16 1.0  ++++ ++++  73 600  601.005  1.0  ++  ++ 
25 5  12.84  2.5  ++++ ++++  74  609  609.043  1.0  ++  ++ 
26 5.6  16.38  2.9  ++++ ++++  75  700  1545.30  2.2  ++  ++ 
27 6 6.38  1.0  ++++ ++++  76  700  697.894  −1.0 ++  ++ 
28 13  15.57  1.1  ++++ ++++  77  710  709.97  −1.0 ++  ++ 
29 19  19.30  1.0  ++++ ++++  78  780  779.896  −1.0 ++  ++ 
30 20  524.55  26.2  +++ ++  79  800 798.863  −1.0 ++  ++ 
31 24  23.99  −1.0 +++ +++  80  860  860.59  1.0  ++  ++ 
32 26  26.03  1.0  +++  +++  81  890  889.222  −1.0 ++  ++ 
33 27  27.18  1.0  +++  +++  82  890  889.127  −1.0 ++  ++ 
34  30  526.07 17.5 +++ ++  83  1100 1103.48 1.0  ++  ++ 
35 32  42.12  1.3  +++  +++  84  1200  1209.95  1.0  ++  ++ 
36 37  37.00  −1.0 +++ +++  85  1200 1193.16  −1.0 ++  ++ 
37 37  35.56  −1.0 +++ +++  86  1400 1399.23  −1.0 ++  ++ 
38 40  10.60  −3.7 +++ +++  87  1400 552.461  −2.5 ++  ++ 
39 50  50.85  1.0  +++  +++  88  1650  1645.71  −1.0 ++  ++ 
40 50  50.17  1.0  +++  +++  89  1650  551.849  −2.9 ++  ++ 
41 58  56.72  −1.0 +++ +++  90  1700  524.94 −3.2 ++  ++ 
42 70  71.11  1.0  +++  +++  91  1800  1821.04  1.0  ++  ++ 
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Table 3. Cont. 
43 70  70.25  1.0  +++  +++  92  1800  1776.13  −1.0 ++  ++ 
44 77  76.65  −1.0 +++ +++  93  1800 1530.73  −1.1 ++  ++ 
45 82  408.48  4.9  +++  ++  94  1900  1901.07  1.0  ++  ++ 
46 109  517.17  4.7  +++  ++ 95  1900  1876.01  −1.0 ++  ++ 
47 110  532.07  4.8  +++  ++ 96  2040  2022.46  −1.0 +  + 
48 130  518.66  3.9  +++  ++ 97  2100  2095.67  −1.0 +  + 
49 130  60.13  −2.1 +++ +++  98  2200 1991.66  −1.1 +  ++ 
50 140  140.46  1.0  +++  +++  99  2400  2386.02  −1.0 +  + 
51 150  514.80  3.4  +++  ++  100  2500  2594.48  1.0  + + 
52 150  149.81  −1.0 +++ +++ 101  2500 2373.56  −1.0 +  + 
53 170  531.86  3.1  +++  ++  102  2600  2653.51  1.0  + + 
54 170  520.35  3.0  +++  ++  103  2600  1980.42  −1.3 +  ++ 
55 190  92.38  −2.0 +++ +++ 104  2700 2668.93  −1.0 +  + 
56 220  519.50  2.3  ++  ++  105  3000  2980.04  −1.0 +  + 
57 250  249.79  −1.0 ++  ++ 106 3100 3021.26  −1.0 +  + 
58 270  40.16  −6.7 ++  ++ 107 3200 3351.54  1.0 +  + 
59 300  546.21  1.8  ++  ++  108  3300  3370.61  1.0  + + 
60 300  521.04  1.7  ++  ++  109  3300  3333.56  1.0  + + 
61 300  301.67  1.0  ++  ++  110  3300  3277.62  −1.0 +  + 
62 300  289.88  −1.0 ++  ++ 111 3700 4354.53  1.1 +  + 
63 370  580.52  1.5  ++  ++  112  4000  1316.33  −3.0 +  ++ 
64 380  531.50  1.3  ++  ++  113  4300  4440.06  1.0  + + 
65 400  517.75  1.2  ++  ++  114  4600  3529.94  −1.3 +  + 
66 400  513.35  1.2  ++  ++  115  4700  4603.40  −1.0 +  + 
67 430  515.92  1.2  ++  ++  116  5000  5036.50  1.0  + + 
68 430  515.00  1.1  ++  ++  117  5860  2779.37  −2.1 +  + 
69 430  431.38  1.0  ++  ++             
a Exp.: Experimental activity; 
b Est.: Estimated activity; 
c Value in the error column represents the ratio of the 
estimated activity to the experimental activity or its negative inverse if the ratio is less than one; 
d Activity 
scale: most active (++++, IC50 < 20 nM); moderately active (+++, ≥20 IC50 < 200 nM); less active (++,  
≥200 IC50 < 2000 nM); inactive (+, IC50 > 2000 nM). 
Eight out of nine of the most active compounds were estimated in the same activity scale, whereas 
the ninth compound was predicted as moderately active. Seventeen out of 26 moderately active 
compounds were estimated in the same scale, whereas the remaining nine were estimated as less active 
compounds. All the 40 less active compounds were estimated in the less active scale. Furthermore, 
only three of the 22 inactive compounds were predicted as less active compounds. Thus, the ability of 
Hypo1 to forecast the activity of test set compounds was very impressive and outstanding. A 
correlation value of 0.928 was achieved between experimental and estimated activities of test set 
compounds. A correlation plot showing the correlation between the experimental and estimated 
activity values of training and test set compounds was generated and displayed in Figure 6. Int. J. Mol. Sci. 2011, 12 9246 
 
Figure 6. The correlation graph between experimental and estimated activity values based on Hypo1. 
 
2.2.2. Fischer Randomization Method 
Another validation method based on Fischer randomization was also performed on the training set 
compounds to verify the quality of Hypo1. In this validation process, a confidence level of 95% was 
selected and thus 19 spreadsheets (Table 4) were generated. 
Table 4. Results of cross-validation by Fischer randomization using DS. 
Trial No.  Total cost  Fixed cost  RMSD  Correlation (r) 
Hypo1 89.663 75.791  1.176  0.942 
Results after randomization 
1 114.486  77.911  1.821  0.858 
2 108.259  72.031  1.796  0.863 
3  98.26 74.85 1.529  0.9 
4 113.25  77.605  1.851  0.851 
5 112.27  77.909  1.729  0.874 
6  108.84  75.77 1.749 0.869 
7 141.304  78.861  2.463  0.717 
8 109.86  72 1.857  0.852 
9 112.265  77.915  1.849  0.851 
10 113.941  77.584  1.774 0.867 
11 101.143  72.068  1.593 0.894 
12 116.666  74.077  1.959 0.834 
13 114.356  69.48 1.97 0.834 
14 98.277  77.638  1.433  0.913 
15 108.878  72.047  1.753 0.872 Int. J. Mol. Sci. 2011, 12 9247 
 
Table 4. Cont. 
16 117.228  78.041  1.961 0.831 
17 102.183  78.085  1.359 0.926 
18 113.597  77.563  1.891 0.843 
19 106.121  74.044  1.706 0.876 
The data obtained from this validation method did not produce any better statistical values 
compared with that of Hypo1. Out of the 19 runs, only three had a correlation value between 0.90 and 
0.92 which was comparatively less than the correlation value of Hypo1. The total cost values of all 
randomized models and RMSD values were higher than Hypo1, which is not appropriate for a good 
pharmacophore model. Therefore, this validation test also endows the Hypo1 with a high level   
of assurance. 
2.3. Search for New Potential Compounds Using Database Screening 
The suggested pharmacophore model Hypo1 developed so far divulges a fairly accurate idea of the 
required molecular features for a new lead. Therefore, Hypo1 was applied as a search query to retrieve 
molecules with novel and desired attributes from chemical databases (Maybridge and Chembridge). A 
total of 2202 hit compounds, 1478 compounds from Maybridge and 724 compounds from Chembridge, 
respectively, were obtained. Molecular properties were calculated for all hit compounds retrieved from 
databases. The 181 hit compounds (124 from Maybridge and 57 from Chembridge database, 
respectively) with an estimated activity value closer to the most active compound in the training set 
were selected for further evaluation. These hits were further filtered by using Lipinsiki’s rule of five 
which evaluates drug-likeness, or determines if a chemical compound with a certain pharmacological 
or biological activity has properties that would make it feasible to be an orally active drug in humans. 
The 49 compounds of Chembridge database and 23 compounds from Maybridge database have 
satisfied the requirements of Lipinsiki’s rule of five for a drug-like compound. Thus, these 72 hit 
compounds that satisfied the Lipinsiki’s rule of five from a total of 181 hits were subjected to 
molecular docking. 
2.4. Molecular Docking 
All of the 20 training set compounds along with the 72 database hits retrieved from the database 
screening process were docked into the protein active site using the GOLD (Genetic Optimization for 
Ligand Docking) docking program. GOLD fitness score which differentiates molecules on account of 
their interacting pattern is calculated for all molecules. The most active compound of training set 
(compound 1) scored a docking score of 66.6 and exhibited various hydrogen-bonding interactions 
with the key active site residues (Figure 7a). Int. J. Mol. Sci. 2011, 12 9248 
 
Figure 7. The molecular docking results: The binding modes and molecular interactions of 
compound  1 of training set (a); HTS12673 (b); BTB02076 (c); JFD00311 (d) at the 
binding site of chymase enzyme. The key active site residues and inhibitors are shown in 
stick and ball-stick forms, respectively. The hydrogen bonds between protein and inhibitors 
are shown in green dashed lines. 
 
Moreover, two of the carbonyl oxygen atoms near the middle ring that mapped on the HBA features 
of “Hypo1” showed hydrogen-bonding interactions with Gly193 and Ser195 residues of the active site. 
Previous studies of chymase have also divulged the importance of Gly193 and Ser195 as key amino 
acids in active site region of the enzyme [9,13]. Along with diverse hydrogen-bonding contacts, the 
phenyl group of compound 1, which was mapped on the HY-AR feature of “Hypo1” showed π···σ 
interactions with the aromatic ring of residue F191. Moreover, compound 1 also showed hydrophobic 
interactions with Y215 and L99 amino acids. Several hit compounds obtained from database screening 
process also showed high GOLD fitness scores and formed interactions with the active site residues. 
The hit compounds that showed a fitness score of more than 66 were selected as final hits for further 
evaluation process. Intriguingly, all the final three compounds were obtained from Maybridge database 
and none from the Chembridge database. Compound HTS12673 which showed an estimated activity 
value of 6.716 nM has scored a GOLD fitness score of 78.73. It has also exhibited key interactions 
with the important amino acids like Gly193, Ser195, Y215, and H57 at the active site of the enzyme 
(Figure 7b). The phenyl part of anisole ring and pyridine ring that mapped over the HY-AR features of Int. J. Mol. Sci. 2011, 12 9249 
 
“Hypo1” instigated the improved binding of this compound through better hydrophobic interactions. 
Compound BTB02076, which was also retrieved from the Maybridge database, with an estimated 
activity value of 8.605 nM has shown a GOLD fitness score of 72.40. This compound has formed 
various close contacts that lead to the important ligand-enzyme interaction such as hydrogen bonding 
interactions with Gly193, Ser195 and hydrophobic interactions with Phe191 amino acid in the active 
site of the enzyme (Figure 7c). Moreover, important π···π interactions between the fused ring system of 
BTB02076 and the side chain imidazole ring of His57 amino acid were also revealed. Furthermore, it 
also showed hydrophobic interactions with Y125 and L99 amino acid residues of protein through the 
hydrophobic groups mapped over HY-AR features of Hypo1. Third hit, JFD00311, with the estimated 
activity value of 4.661 nM and GOLD fitness score of 74.51 has formed hydrogen bond network with 
the active site residues Gly193, and Ser195 (Figure 7d). The benzene rings and oxygen atoms of the 
benzenesulfonic acid moieties in this hit compound that overlaid the HY-AR and HBA features of 
“Hypo1”, respectively, enabled considerable hydrophobic and polar interactions with the important 
amino acids in the active site. The mapping of these top three database final hits on Hypo1 and their 
2D molecular structures are depicted in Figures 8 and 9, respectively.  
Figure 8. Pharmacophore mapping of three final hit compounds HTS12673 (a); 
BTB02076 (b) and JFD00311(c) over the selected pharmacophore model Hypo1. 
 
Figure 9. 2D molecular structures of hit compounds HTS12673 (a), BTB02076 (b), and 
JFD00311(c). 
 
All three hit compounds have mapped the entire features of the best pharmacophore model, Hypo1. 
Thus, in the design of potent inhibitors of chymase, compounds HTS12673, BTB02076, and 
JFD00311 which showed important results with respect to all properties such as estimated activity, Int. J. Mol. Sci. 2011, 12 9250 
 
calculated drug-like properties and better GOLD fitness scores can be proposed as potential leads. 
Novelty search using SciFinder Scholar and PubChem compound search has also ascertained that 
these hits were not reported earlier for chymase inhibition. 
2.5. Density Functional Theory Calculations 
2.5.1. Analysis of Orbital Energies 
The electrostatic features impacting the inhibitory effect of chymase inhibitors have been 
investigated aiming at providing useful information for understanding the structure inhibition 
relationships of chymase inhibitors. Structures of the most and least active compounds of the training 
set are optimized along with the three final database hit compounds at B3LYP/6-31G* level. 
Statistically significant factors such as HOMO, LUMO, and MESP, for all compounds are calculated. 
According to Fukui’s frontier orbital approximation, the frontier orbitals HOMO and LUMO of a 
chemical species are very important in defining its reactivity. Fukui first recognized the importance of 
frontier orbitals as principal factors governing the ease of chemical reactions and the stereoselective 
path while Parr and Yang demonstrated that most frontier theories can be rationalized from DFT.  
When the whole dataset of molecules was taken into account, an apparent trend of inhibitory 
activity (IC50) data with an increase in HOMO energy was observed (Figure 10). 
Figure 10. HOMO energies (eV) of chymase inhibitors along with potent hits. 
 
For all compounds, HOMO energy ranges between −5.619 and −6.415 eV. High value of EHOMO is 
likely to indicate a tendency of the molecule to donate electrons to appropriate acceptor molecule of 
low empty molecular orbital energy. The correlation of HOMO energies with IC50 data indicates that 
the HOMO of the inhibitor may transfer its electrons to less energy, LUMO, of some amino residues in 
the active site of chymase. The calculations show that compounds 1 and 20 have shown the highest 
(−5.873 eV) and lowest (−6.415 eV) HOMO level energies respectively. This trend is in good 
agreement with the experimental observations suggesting that compounds 1 and 20 have exhibited the 
highest (0.46 nM) and lowest (5900 nM) inhibitory profile, respectively, in all investigated chymase Int. J. Mol. Sci. 2011, 12 9251 
 
inhibitors. While BTB (BTB02076) has shown highest (−5.619 eV) HOMO level energy among hit 
compounds even higher than HOMO energy level of compound 1, the other two hit compounds also 
showed higher EHOMO than the least active compound of the data set. In a previous study, a high 
HOMO energy level also played an important part in activity of the most active dual and selective 
LOX inhibitors [61]. Moreover, a clear trend between the inhibitory activity (IC50) data and LUMO 
energy of all compounds was also revealed. For all compounds, LUMO energy ranged between −0.631 
and  −2.275 eV. Compound 1 and BTB showed highest LUMO level energies; and least active 
compounds 19 and 20 demonstrated LUMO with lowest energies. 
HOMO and LUMO sites are plotted onto the molecular surface of most active (1) and least 
active (20) compounds of the data set along with the two hit (BTB, HTS) compounds (Figure 11). 
Figure 11. Plots of HOMO (a) and LUMO (b) of most active (1), and least active (20) 
compounds along with potent hits BTB (BTB02076) and HTS (HTS12673). 
 
Most often, the heteroaromatic rings, which contain the heteroatoms such as nitrogen and oxygen, 
are the regions in all these compounds that can act as electron donors or acceptors to the active site of Int. J. Mol. Sci. 2011, 12 9252 
 
the chymase. Experimental study also deduced that introduction of heteroatoms to the inhibitor 
compound enhanced its stability in human plasma (20). For instance, the placement of an ethoxy  
group in compound 2 instigated its stability. Electron donor rings can be identified as those with the 
greatest electron density from the HOMO. In the case of compound 1, HOMO is scattered over the  
4-methylpiperazine moiety together with the carbonyl group and LUMO is spread over the region  
2-hydroxyl-4-oxoazetidine containing heteroatoms like oxygen and nitrogen. Docking results also 
showed that this region of compound 1 is involved in important interactions with the key residues of 
protein. For compound 20, HOMO is composed of aniline ring and LUMO spreads over sulfonyl and 
benzoic acid groups. LUMO plot over methylbenzenesulfonamide group in hit compounds BTB 
showed hydrogen bonding interactions with important amino acids Gly193 and Ser195 at the active 
site of the enzyme. Whereas the HOMO plot is scattered on 2-methoxyphenol group and dihydroquinazolin 
moiety, the six membered ring part of dihydroquinazolin group is involved in important π···π 
interactions with the side chain imidazole ring of His57 amino acid. For HTS hit compound, HOMO 
and LUMO are composed of methoxybenzene, benzoindazole moieties, and oxadiazole substituted 
pyridine moiety, respectively. Overlay of HTS on “Hypo1” and its docking with the protein also 
speculated the involvement of these groups in key interactions with the active site of protein. The 
effect of the orbital energies on the inhibition activities can be associated with the charge transfer, π···π, 
or π···σ stacking between inhibitors and aromatic amino acid residues in the binding site of chymase. 
The result of molecular docking studies on chymase inhibitors also proved the presence of such kind  
of interactions.  
2.5.2. Molecular Electrostatic Potential (MESP) Profiles 
Electrostatic potential is widely used in characterizing molecules, especially for biomolecules, and 
takes special effect in the biomolecular recognition and in the prediction of the functional sites [62]. 
Nam et al. reported their discovery that electrostatic interactions accounted for the majority of the rate 
acceleration in the mechanism of RNA transphosphorylation in solutions catalyzed by the hairpin 
ribozyme [63]. Daga and Doerksen have stated the binding mode and the role of stereoelectronic 
properties in binding of spiroquinazolinones showing phosphodiesterase 7 (PDE7) inhibitory   
activities [64]. Recently, the electrostatic funnel illuminated from three-dimensional mapping of the 
electrostatic potential was reported by Dehez et al., driving the diphosphate nucleotide rapidly toward 
the bottom of the internal cavity of membrane-protein mitochondrial ADP/ATP carrier by forming a 
privileged passageway [65]. Considering these discoveries comprehensively, we supposed that the 
electrostatic potential of the inhibitor also played a significant role in the binding and interaction with 
chymase together with orbital energy and consequently influenced the inhibition effect. The 3D 
isosurface maps of MESP were interpolated on the electron density surfaces of constant electron 
charge density (0.0004 e/au
3). As is well known, the electrostatic potential is defined as the interacted 
energy of a positively remote charge point with the nuclei and the electrons of a molecule. The   
3D plots of electron density (ED) and the MESP for compounds 1, 20, BTB and HTS are shown  
in Figure 12. Int. J. Mol. Sci. 2011, 12 9253 
 
Figure 12. Differential maps of total density (a) and MESP (b) of most active, 1, and least 
active, 20, compounds along with potent hits BTB (BTB02076) and HTS (HTS12673). 
The red and the blue color represent the electronegative and electropositive potentials 
whereas the green represents a potential halfway between the two extremes. 
 
The coloring area of the surface represents the overall molecular charge distribution with the 
electrostatic potential. As for the compounds in this study, the electronegative potential (MESPmin) was 
coded with red on the MESP maps in a range from 202.16 to 152.27 kcal/mol indicating a strongest 
attraction while the interpolated blue map represents the electropositive potential (MESPmax) of a 
strongest repulsion varying from 15.68 to 42.67 kcal/mol. The predominance of green region in the 
MESP surfaces corresponds to a potential halfway between the two extremes that are indicated in red 
and blue colors, respectively.  Int. J. Mol. Sci. 2011, 12 9254 
 
MESP plotted onto constant electron density surface for most active compound 1 showed the most 
electronegative potential region (red color) over the oxygen atom of the carbonyl group near the 
piperazine moiety. However, in the case of the least active compound 20, most negative potentials due 
to sulfonyl and carbonyl oxygen atoms are missing. For hit compounds, appearance of localized 
negative potential regions located at the oxygen atoms of the carbonyl and sulfonyl groups and 
nitrogen of the pyridine ring are consistent with the docking results which recognized this region as 
hydrogen bond acceptor. Moreover, one more prominent localized negative charged region protruding 
over the oxadiazole group was oriented adjacent to Gly193, to be recognized as a hydrogen bond 
acceptor. The strong electrostatic interaction of the negative potential with key residues Gly193 and 
Ser195, namely the formation of the hydrogen bond, will enhance the inhibition effect substantially 
together with the orbital interaction through the exchange of energy. The blue electropositive maps of 
these compounds were mainly distributed over the methyl group. The hydrogen atoms attached to the 
six-membered rings also bear the maximum brunt of positive charge (blue region). Due to the 
accumulation of positive potential, these moieties exhibited π···π and π···σ interactions with the 
aromatic residues of active site. These molecular electrostatic potential features are also in concert 
with the key chemical features (HBA and HY-AR) of pharmacophore model (Hypo1) which was 
successfully employed as a 3D structural query for virtual screening of databases for the identification 
of new potent chymase inhibitors. Thus electrostatic potential of the inhibitors can play a significant 
role in the binding and interaction with chymase together with orbital energies, and consequently 
influence the inhibition effect.  
3. Materials and Methods 
3.1. Pharmacophore Modeling 
3.1.1. Selection of Training Set Compounds and Diverse Conformation Generation 
A set of 117 structurally distinct compounds reported as chymase inhibitors with their diverse 
experimentally known inhibitory activity (IC50) data was compiled from the literature such as life 
science journals [14–20,55,66–68]. All of the inhibitory activities were obtained using the same 
biological assay method [14]. To form a training set, 20 compounds with distinctive structural motif 
and wide activity range (0.46 to 5900 nM) were selected. For all compounds in the training set, energy 
minimization process was performed with CHARMM  forcefield. Poling algorithm was applied to 
generate a maximum of 255 diverse conformations with the energy threshold of 20 kcal·mol
−1 above 
the calculated energy minimum for every compound in the dataset. These conformers were generated 
using Diverse Conformer Generation protocol running with Best/Flexible conformer generation option 
as available in Accelrys Discovery Studio v2.5 (DS), Accelrys, San Diego, CA, USA. This method 
ensures the best coverage of conformational space by performing a more rigorous energy minimization 
in both torsional and cartesian space by using poling algorithm.  Int. J. Mol. Sci. 2011, 12 9255 
 
3.1.2. Pharmacophore Model Generation 
All the 20 training set compounds associated with their conformations were submitted to the 
HypoGen module of DS. The HypoGen algorithm implemented for the pharmacophore hypothesis 
generation process is executed in three phases, namely, constructive, subtractive, and optimization 
phases. In constructive phase, identification of features common to the most active compounds takes 
place whereas all pharmacophoric features that are also present in the least active compounds are 
removed in subtractive phase. Finally, in the optimization phase, the hypothesis score is improved by 
regression parameters which are used for the estimation of the activity value of each training set 
compound. The relationship between the geometric fit value and activity value is utilized for this 
computation. Pharmacophore hypotheses showing best correlation in the 3D arrangement of features in 
a given training set compounds with the corresponding pharmacological activities are formed and 
ranked. Several structure activity relationship (SAR) pharmacophore models were derived from 
training set compounds using HypoGen module of DS. In this study, the top 10 hypotheses which were 
returned by the hypotheses generation process with significant statistical parameters were selected for 
further calculations. 
3.1.3. Pharmacophore Model Validation and Database Searching 
The generated quantitative pharmacophore model was validated to find out whether it is competent 
enough to identify the active structures and estimate their activity values precisely. This validation 
process was performed based on test set prediction and Fischer randomization methods. In developing 
statistical models, the following three cross-validation methods are often used to examine a model or 
predictor for its effectiveness in practical application: independent dataset test, subsampling test, and 
jackknife test [69]. However, of the three test methods, the jackknife test is deemed the most   
objective [29]. The reasons are as follows. (i) For the independent dataset test, although all the samples 
used to test the model or predictor are outside the training dataset used to train it so as to exclude the 
“memory” effect or bias, the way of how to select the independent samples to test the model or 
predictor could be quite arbitrary unless the number of independent proteins is sufficiently large. This 
kind of arbitrariness might result in completely different conclusions. For instance, a model or 
predictor achieving a higher success rate than the other model or predictor for a given independent 
testing dataset might fail to keep so when tested by another independent testing dataset [69]; (ii) For 
the subsampling test, the concrete procedure usually used in literatures is the 5-fold, 7-fold or 10-fold 
cross-validation. The problem with this kind of subsampling test is that the number of possible 
selections in dividing a benchmark dataset is an astronomical figure even for a very simple dataset, as 
elucidated demonstrated by Equations 28–30 in [70]. Therefore, in any actual subsampling cross-validation 
tests, only an extremely small fraction of the possible selections are taken into account. Since different 
selections will always lead to different results even for a same benchmark dataset and a same model or 
predictor, the subsampling test cannot avoid the arbitrariness either. A test method unable to yield a 
unique outcome cannot be deemed as a good one; (iii) In the jackknife test, all the samples in the 
benchmark dataset will be singled out one-by-one and tested by the model or predictor trained by the 
remaining samples. During the process of jackknifing, both the training dataset and testing dataset are Int. J. Mol. Sci. 2011, 12 9256 
 
actually open, and each sample will be in turn moved between the two. The jackknife test can exclude 
the “memory” effect. Also, the arbitrariness problem as mentioned above for the independent dataset 
test and subsampling test can be avoided because the outcome obtained by the jackknife cross-validation 
is always unique for a given benchmark dataset. Accordingly, the jackknife test has been increasingly 
and widely used by those investigators with strong math background to examine the quality of various 
predictors (see e.g., [30,71–75]). However, to reduce the computational time, we adopted the 
independent testing dataset cross-validation in this study as done by many investigators with SVM as 
the prediction engine. A test set comprising 97 compounds with experimentally known chymase 
inhibitory activity values was used in test set prediction method. Ligand Pharmacophore Mapping 
protocol running with BEST/Flexible conformation generation option was used to map the test set 
compounds. Fischer randomization method as available in DS was applied on training set compounds 
to prove that the generated pharmacophore model was not obtained by chance. A pharmacophore is 
only useful as a predictive model in finding novel, potential leads suitable for further development 
only if it is able to detect the compounds with known inhibitory activity. In order to identify new 
potential lead compounds, the selected pharmacophore model was subsequently used as 3D structural 
search query to screen the Maybridge and Chembridge chemical databases consisting of 60,000 and 
50,000 of structurally assorted compounds, respectively. All queries were performed using   
Ligand Pharmacophore Mapping protocol running with Best/Flexible search method in DS. To be 
retrieved as a hit, a molecule must fit all the features of the pharmacophore hypothesis. The hits 
obtained through database screening were further filtered using Lipinsiki’s rule of five in order to carry 
only drug-like compounds in further studies. 
3.2. Molecular Docking 
Computational docking operation is a useful vehicle for investigating the interaction of a protein 
receptor with its ligand and revealing their binding mechanism as demonstrated by a series of   
studies [18,46,76–84]. Docking plays a significant role in predicting binding orientation and affinity of 
small molecule drug candidates to their protein targets with known 3D structures [85,86]. Hence, 
docking serves as an important tool in the rational computer-assisted drug design [87,88]. GOLD 4.1 
(Genetic Optimization for Ligand Docking) from Cambridge Crystallographic Data center, UK uses a 
genetic algorithm for docking ligands into protein binding sites to explore the full range of ligand 
conformational flexibility with partial flexibility of protein [89]. In this study, it has been utilized for 
the docking of training set compounds along with the new hits retrieved from chemical databases. 
Protein coordinates from the crystal structure of chymase co-crystallized with β-ketophosphonate 
(PDB ID: 1T31), determined at a resolution of 1.9 Å were used to define the active site [9]. All the 
water molecules present in the protein were removed and hydrogen atoms were added. The active site 
was defined with a 10 Å radius around the ligand present in the crystal structure. At the end of the 
computation, the 10 top-scoring conformations of every ligand were saved. Early termination option 
was applied to pass over the genetic optimization calculation when any five conformations of a 
particular compound were envisaged within an RMS deviation value of 1.5 Å. The GOLD fitness score 
is calculated from the contributions of hydrogen bond and van der Waals interactions between the Int. J. Mol. Sci. 2011, 12 9257 
 
protein and ligand, intramolecular hydrogen bonds and strains of the ligand. The protein–ligand 
interactions were scrutinized by DS. 
3.3. Density Functional Theory (DFT) Calculations 
As far as computational technique is considered, many practices have ascertained that DFT, which 
takes into account the exchange and correlation effects effectively, is most likely one of the best 
methods to study medium-size or larger molecular systems and appropriate for QSAR study, with 
exhibiting excellent performance than semiempirical method or some other ab initio methods. 
Complete geometry optimization for data set compounds was carried out using DFT with Becke’s 
three-parameter exchange potential and the Lee-Yang-Parr correlation functional (B3LYP), using basis 
set 6-31G* level [90]. A useful kind of net atomic charges, called electrostatic potential (ESP)-fitting 
charges, were derived from the DFT calculated molecular electrostatic potential distribution using 
CHelpG method, which produces charges fit to the electrostatic potential at points selected. 
Vibrational frequencies were computed at the same B3LYP/6-31G* level to characterize the stationary 
points on the corresponding potential energy surfaces. All calculations were performed using the 
Gaussian 03 suite of programs.  
3.3.1. Data Set of DFT Study 
Based on structural diversity and wide biological activity range, four chymase inhibitors including 
most and least active compounds, were selected from the training set. While, three final hits 
BTB02076, HTS12673, JFD00311 retrieved from Maybridge database by the selected pharmacophore 
model, which showed important results with respect to all properties like molecular interactions with 
the active site components, estimated activity, calculated drug-like properties, and high GOLD fitness 
score, were also selected. Thus, data set employed for  DFT study consisted of seven compounds. 
Various quantum-chemical descriptors such as LUMO, HOMO, and locations of molecular 
electrostatic potentials (MESP), were computed.  
3.3.2. Calculation of Molecular Electrostatic Potential (MESP) 
The mapping of the electrostatic potential is an established technique for investigation of 
biologically active compounds because it plays a key role in the initial steps of ligand-receptor 
interactions. The formatted checkpoint files of the compounds generated by the geometric optimization 
computation were used as input for CUBEGEN program interfaced with Gaussian 03 program to 
compute the MESP. The MESP isopotential surfaces was produced and superimposed onto the total 
electron density surface (0.0004 e/au
3). The electrostatic potential of the whole molecule is finally 
obtained by superimposing the electrostatic potentials upon the total electron density surface of   
the compound. Int. J. Mol. Sci. 2011, 12 9258 
 
4. Conclusion 
Since user-friendly and publicly accessible web-servers represent the future direction for 
developing practically more useful models or predictors [91], we shall make efforts in our future work 
to provide a web-server for the method presented in this study. 
Combining various theoretical methods like pharmacophore modeling, database screening, 
molecular docking and DFT calculations, an investigation for identification of novel chymase 
inhibitors and to specify the key factors crucial for the binding and interaction between chymase and 
inhibitors was performed. The highly correlating (r = 0.942) pharmacophore model (Hypo1) with two 
hydrogen bond acceptors, and three hydrophobic aromatic features was generated. After successfully 
validating “Hypo1” using test set and Fischer randomization methods, it was further used in database 
screening. Hit compounds were subjected to various drug-like filtrations and molecular docking 
studies. Finally, three structurally diverse compounds with high estimated activity and strong 
molecular interactions with key active site amino acids were identified. Furthermore, a DFT study, 
which articulated the influence of the electrostatic features of compounds on their inhibitory activity 
well, was performed. Analysis of orbital energies and plots of MESP has shown very clear trends 
between electronic properties and inhibitory activity (IC50) data. An increasing trend was observed 
between IC50 and HOMO energy values. The molecular electrostatic potential features were also 
consistent with the key chemical features of “Hypo1” thus successfully validating “Hypo1” by the 
DFT method. Therefore, the results of this study will be helpful, not only in the development of new 
potent hits for chymase, but also in providing a better understanding of the interaction between the 
chymase and inhibitors. This will in turn assist in the rational design of novel potent enzyme inhibitors. 
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